Clinical trials: Leukemia, Acute Myeloid (AML), open to volunteers
AML, Childhood, Relapse/Recurrence
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
- Conditions
- AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
- Trial name
- NCT06316960
- Testing
- Avapritinib, Azacitidine Injection, Decitabine Injection
- Where
- 12 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Soochow University
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
This study is a clinical trial to evaluate the tolerability and pharmacokinetics of TQB3455 tablets in patients with hematological malignancies. TQB3455 is an isocitrate dehydrogenase 2(IDH2) inhibitor .
- Trial name
- NCT06550713
- Testing
- TQB3455 tablet+Azacitidine for Injection
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AML, Adult
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as…
- Trial name
- NCT06297772
- Testing
- Decitabine, Fludarabine Injection, Busulfan Injection
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Ruijin Hospital
ACUTE MYELOID LEUKEMIA; AML
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT06387420
- Testing
- AK117, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Akeso
AML, Adult, Minimal Residual Disease
Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax
The goal of this no-profit, multicenter, biological, non-pharmacologic study is to evaluate minimal residual disease (MRD) in patients treated with Azacitidine and Venetoclax according to clinical practice.
- Trial name
- NCT06090786
- Testing
- MRD assessment
- Volunteers
- 225 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
AML, Adult
Novel Approaches to Target MECOM/EVI1 in AML
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
- Trial name
- NCT05839392
- Testing
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
AML, Adult, Minimal Residual Disease
A Study of Chidamide With AZA in MRD Positive AML After Transplant
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary…
- Trial name
- NCT06066905
- Testing
- chidamide and azacitidine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
AML
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients.
- Trial name
- CLAG (NCT05875649)
- Testing
- CLAG
- Where
- 2 sites in China
- Volunteers
- 137 people
- Sponsor
- Nanfang Hospital, Southern Medical University
AML, Adult
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
- Trial name
- SAV (NCT05736965)
- Testing
- Selinexor, Azacitidine, Venetoclax
- Where
- 19 sites in China
- Volunteers
- 58 people
- Sponsor
- Shanghai Tong Ren Hospital
Acute Myeloid Leukemia (AML) in Remission
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who…
- Trial name
- NCT05404906
- Testing
- Azacitidine, Venetoclax, Supportive care
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Acute Myeloid Leukemia (AML)
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule.
- Trial name
- NCT05445154
- Testing
- SKLB1028 Dose Escalation
- Where
- China
- Volunteers
- 58 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
AML, Adult, MDS
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
This is a randomized clinical trial that randomizes between treatment principles. The study will investigate if precision therapy determined by a tumour board is better than standard treatment for acute myeloid leukaemia (AML)…
- Trial name
- PALM (NCT05025098)
- Testing
- Standard therapy, Precision therapy
- Where
- Norway
- Volunteers
- 36 people
- Sponsor
- University Hospital, Akershus